Nanoform Finland Oyj

Equities

NANOFH

FI4000330972

Biotechnology & Medical Research

Delayed Nasdaq Helsinki Other stock markets 05:06:44 2024-05-16 am EDT			5-day change	1st Jan Change
1.944 ^EUR	+1.89%		-1.24%	+21.01%

Apr. 11	Nanoform Finland to Deliver Nanomedicine Technology to Japan	MT
Apr. 11	Nanoform Enters Exclusive Partnership with CBC to Bring Best-In-Class Nanomedicine Technology to Japan	CI

Nanoform Finland Plc Elects Cynthia Schwalm as New Member of the Board of Directors, Member of Audit and Compensation Committee

September 01, 2020 at 06:00 am EDT

Nanoform Finland Plc announced that at its EGM held on September 1, 2020, the shareholders elected Cynthia Schwalm as a new member of the board of directors of the company. The board of directors elected Cynthia Schwalm as a member of the audit and compensation committee.

Latest news about Nanoform Finland Oyj

Nanoform Finland to Deliver Nanomedicine Technology to Japan	Apr. 11	MT
Nanoform Enters Exclusive Partnership with CBC to Bring Best-In-Class Nanomedicine Technology to Japan	Apr. 11	CI
Nanoform Teams Up with PlusVitech to Repurpose Anti-Nausea Drug for Lung Cancer Treatment	Apr. 09	MT
Nanoform Finland plc and Plusvitech Partner to Repurpose Aprepitant as A Treatment for Lung Cancer	Apr. 09	CI
Nanoform Finland Oyj Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Nanoform Finland Oyj Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 29	CI
Transcript : Nanoform Finland Oyj, 2023 Earnings Call, Feb 29, 2024	Feb. 29
Nanoform Finland plc Receives Positive Results from its Own Pre- Clinical, In-Vivo Study of a Nanocrystalline-Enabled Apalutamide Oral Formulation	Feb. 29	CI
Transcript : Nanoform Finland Oyj - Special Call	Jan. 26
Nanoform Announces Important Milestone with Promising Clinical Results for Patient-Centric Nanotechnology-Enhanced Enzalutamide	Jan. 26	CI
Nanoform Finland Starts Clinical Trial for Nanocrystalline Alternative of Prostrate Cancer Drug	Jan. 05	MT
Nanoform Finland plc Commences Relative Bioavailability Study of Nanotechnology-Enhanced Enzalutamide	Jan. 05	CI
Transcript : Nanoform Finland Oyj, Q3 2023 Earnings Call, Nov 22, 2023	Nov. 22
Nanoform Finland Oyj Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 22	CI
Nanoform Finland Signs Licensing Deal for AI Technology with AstraZeneca	23-10-23	MT
Nanoform Grant Global STARMAP[®] AI License to AstraZeneca	23-10-23	CI
Transcript : Nanoform Finland Oyj, Q2 2023 Earnings Call, Aug 24, 2023	23-08-24
Nanoform Finland Oyj Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-24	CI
Finland’s Nanoform, Celanese to Advance Partnership in Nanoparticle-enabled Drug Delivery Study	23-06-15	MT
Nanoform and Celanese Demonstrate Enhanced Drug Delivery Through the Power of Smaller Implants	23-06-15	CI
Transcript : Nanoform Finland Oyj, Q1 2023 Earnings Call, May 25, 2023	23-05-25
Nanoform Finland Oyj Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-25	CI
Finnish Medicines Agency Renews Nanoform's GMP License and Nanoform Starts Clinical API Manufacturing of Blockbuster Medicine Candidate	23-05-09	CI
Nanoform Finland plc Announces Board Appointments	23-04-12	CI
Transcript : Nanoform Finland Oyj, Q4 2022 Earnings Call, Feb 28, 2023	23-02-28

Chart Nanoform Finland Oyj

Duration

Period

More charts

Company Profile

Nanoform Finland Oyj is a Finland-based company that operates in the global pharmaceutical industry. The Company is an early-stage growth Company that develops various nanoforming technologies for application in the field of nanomedicine. Nanoform Finland Oyjâs business is to offer expert services in nanotechnology as well as drug particle engineering for global pharma and biotech industry. Nanoform Finland Oyj is the Parent Company of the Nanoform Group, and it has one subsidiary - Nanoform USA Inc. The Group production, research and development functions operate in Finland. The Groupâs strategy is to sell nanotechnological services widely to minimize the dependence from single customers or projects.

Sector

Biotechnology & Medical Research

Calendar

2024-05-20 - Global DDF Summit

More about the company

Income Statement Evolution

More financial data

Ratings for Nanoform Finland Oyj

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.908 EUR

Average target price

4.4 EUR

Spread / Average Target

+130.61%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
NANOFORM FINLAND OYJ	+21.01%	177M
MODERNA, INC.	+29.77%	49.46B
IQVIA HOLDINGS INC.	+1.00%	42.58B
LONZA GROUP AG	+49.62%	42.49B
CELLTRION, INC.	-5.26%	29.09B
ICON PUBLIC LIMITED COMPANY	+13.68%	26.61B
ALNYLAM PHARMACEUTICALS, INC.	-22.99%	18.64B
BIO-TECHNE CORPORATION	+8.22%	13.16B
MEDPACE HOLDINGS, INC.	+32.41%	12.55B
UNITED THERAPEUTICS CORPORATION	+24.01%	12.1B

Other Biotechnology & Medical Research